Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐... by Ming‐Han Yang, Chiun‐Sheng Huang, Dwan‐Ying Chang, Fu‐Chang Hu, Shu‐Min Huang, Po‐Hsiang Huang, I‐Chun Chen, Tom Wei‐Wu Chen, Ching‐Hung Lin, Yen‐Shen Lu

Get full text